Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MGTX Stock Forecast 2026-2027
$7.24
Current Price
$582.75M
Market Cap
Buy 8
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to MGTX Price Targets
+590.6%
To High Target of $50.00
+238.4%
To Median Target of $24.50
+93.4%
To Low Target of $14.00
MGTX Price Momentum
-3.6%
1 Week Change
-18.8%
1 Month Change
+22.5%
1 Year Change
-8.9%
Year-to-Date Change
-25.6%
From 52W High of $9.73
+59.1%
From 52W Low of $4.55
📊 TOP ANALYST CALLS
Did MGTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if MeiraGTx is one of their latest high-conviction picks.
Latest MGTX Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, MGTX has a bullish consensus with a median price target of $24.50 (ranging from $14.00 to $50.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $7.24, the median forecast implies a 238.4% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MGTX Analyst Ratings
8
Buy
0
Hold
0
Sell
MGTX Price Target Range
Low
$14.00
Average
$24.50
High
$50.00
Current: $7.24
Latest MGTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MGTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 24, 2025 | HC Wainwright & Co. | Mitchell S. Kapoor | Buy | Initiates | $20.00 |
| Nov 14, 2025 | RBC Capital | Lisa Walter | Outperform | Maintains | $16.00 |
| Nov 14, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $35.00 |
| Nov 11, 2025 | Piper Sandler | Allison Bratzel | Overweight | Maintains | $30.00 |
| Nov 11, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $35.00 |
| Oct 21, 2025 | Raymond James | Christopher Raymond | Strong Buy | Initiates | $29.00 |
| Aug 15, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $35.00 |
| May 14, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $35.00 |
| Mar 17, 2025 | RBC Capital | Luca Issi | Outperform | Maintains | $13.00 |
| Feb 24, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $36.00 |
| Nov 18, 2024 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $36.00 |
| Nov 14, 2024 | RBC Capital | Luca Issi | Outperform | Maintains | $11.00 |
| Aug 13, 2024 | RBC Capital | Luca Issi | Outperform | Maintains | $9.00 |
| Jul 31, 2024 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $36.00 |
| Mar 15, 2024 | RBC Capital | Luca Issi | Outperform | Reiterates | $11.00 |
| Aug 11, 2023 | Chardan Capital | Geulah Livshits | Buy | Reiterates | $41.00 |
| Aug 11, 2023 | RBC Capital | Luca Issi | Outperform | Maintains | $11.00 |
| May 12, 2023 | Piper Sandler | Christopher Raymond | Overweight | Maintains | $25.00 |
| Mar 16, 2023 | Chardan Capital | Geulah Livshits | Buy | Maintains | $41.00 |
| Mar 15, 2023 | RBC Capital | Luca Issi | Outperform | Maintains | $22.00 |
MeiraGTx Holdings plc (MGTX) Competitors
The following stocks are similar to MeiraGTx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
MeiraGTx Holdings plc (MGTX) Financial Data
MeiraGTx Holdings plc has a market capitalization of $582.75M with a P/E ratio of -3.4x. The company generates $27.42M in trailing twelve-month revenue with a 28.5% profit margin.
Revenue growth is -96.2% quarter-over-quarter, while maintaining an operating margin of -11,232.0% and return on equity of -611.4%.
Valuation Metrics
Market Cap
$582.75M
Enterprise Value
$669.66M
P/E Ratio
-3.4x
PEG Ratio
-0.3x
Price/Sales
20.9x
Growth & Margins
Revenue Growth (YoY)
-96.2%
Gross Margin
+23.7%
Operating Margin
-11,232.0%
Net Margin
+28.5%
EPS Growth
-96.2%
Financial Health
Cash/Price Ratio
+2.5%
Current Ratio
0.2x
Debt/Equity
-2.2x
ROE
-611.4%
ROA
-41.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
MeiraGTx Holdings plc (MGTX) Business Model
About MeiraGTx Holdings plc
What They Do
Develops novel gene therapies for serious diseases.
Business Model
MeiraGTx operates as a clinical-stage gene therapy company, focusing on creating innovative treatments for genetic disorders and serious diseases. The company generates revenue through its pipeline of gene therapy programs, which target conditions like ocular diseases and neurodegenerative disorders, leveraging proprietary technology to modify gene expression and deliver long-lasting therapies.
Additional Information
With a strong emphasis on industrial scalability and technological innovation, MeiraGTx is positioned in the biotechnology and pharmaceuticals sectors, attracting attention for its potential medical contributions. The company has established strategic partnerships in manufacturing and research, enhancing its role in personalized medicine and impacting a wide range of therapeutic areas.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
409
CEO
Dr. Alexandria Forbes Ph.D.
Country
United States
IPO Year
2018
Website
meiragtx.comMeiraGTx Holdings plc (MGTX) Latest News & Analysis
Latest News
Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference
1 month ago
Quick Summary
Graviton Bioscience's CEO, Samuel Waksal, will speak at the 8th Annual Evercore HealthCONx Conference, discussing their ROCK2 inhibitors for various disorders.
Why It Matters
Graviton Bioscience's participation in a prominent conference highlights its visibility and potential for partnerships, which could influence stock performance and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
MeiraGTx Holdings plc (Nasdaq: MGTX) reported its Q3 2025 financial and operational results on November 13, 2025, and provided a corporate update.
Why It Matters
MeiraGTx's Q3 results and corporate update indicate its financial health and operational progress, impacting investor confidence and potential stock valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
MeiraGTx Holdings PLC (MGTX) reported a quarterly loss of $0.62 per share, worse than the expected loss of $0.50 and compared to a loss of $0.54 per share a year prior.
Why It Matters
MeiraGTx's larger-than-expected quarterly loss signals potential operational or financial challenges, which may impact investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
MeiraGTx partners with Eli Lilly for AAV-AIPL1 gene therapy, receiving $75M upfront and potential $400M in milestones, enhancing financial stability and reducing dilution risk.
Why It Matters
MeiraGTx’s partnership with Eli Lilly boosts its finances and reduces dilution risk, while showcasing its innovative pipeline, which could enhance long-term growth potential and investor confidence.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
MeiraGTx Holdings has partnered with Eli Lilly in a deal potentially worth over $475 million for rights to an experimental gene therapy for a rare vision loss disorder.
Why It Matters
The $475 million deal enhances MeiraGTx's financial outlook and validates its gene therapy, potentially increasing its market value and attracting investor interest in innovative treatments.
Source: Reuters
Market Sentiment:
Positive
Quick Summary
MeiraGTx Holdings plc has announced a strategic collaboration with Eli Lilly focused on ophthalmology, enhancing its position in the genetic medicines sector.
Why It Matters
MeiraGTx's collaboration with Eli Lilly enhances its growth prospects in ophthalmology, potentially increasing market share and driving innovation, which could positively impact stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MGTX Stock
What is MeiraGTx Holdings plc's (MGTX) stock forecast for 2026?
Based on our analysis of 9 Wall Street analysts, MeiraGTx Holdings plc (MGTX) has a median price target of $24.50. The highest price target is $50.00 and the lowest is $14.00.
Is MGTX stock a good investment in 2026?
According to current analyst ratings, MGTX has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $7.24. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MGTX stock?
Wall Street analysts predict MGTX stock could reach $24.50 in the next 12 months. This represents a 238.4% increase from the current price of $7.24. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is MeiraGTx Holdings plc's business model?
MeiraGTx operates as a clinical-stage gene therapy company, focusing on creating innovative treatments for genetic disorders and serious diseases. The company generates revenue through its pipeline of gene therapy programs, which target conditions like ocular diseases and neurodegenerative disorders, leveraging proprietary technology to modify gene expression and deliver long-lasting therapies.
What is the highest forecasted price for MGTX MeiraGTx Holdings plc?
The highest price target for MGTX is $50.00 from at , which represents a 590.6% increase from the current price of $7.24.
What is the lowest forecasted price for MGTX MeiraGTx Holdings plc?
The lowest price target for MGTX is $14.00 from at , which represents a 93.4% increase from the current price of $7.24.
What is the overall MGTX consensus from analysts for MeiraGTx Holdings plc?
The overall analyst consensus for MGTX is bullish. Out of 9 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $24.50.
How accurate are MGTX stock price projections?
Stock price projections, including those for MeiraGTx Holdings plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 13, 2026 10:33 AM UTC